AbbVie Inc. logo

AbbVie Inc. (ABBV)

Market Closed
17 Jul, 20:00
XMEX XMEX
MX$
4,495. 00
+163.01
+3.7629%
MX$
- Market Cap
42.2 P/E Ratio
1.58% Div Yield
42 Volume
10.28 Eps
MX$ 4,331.99
Previous Close
Add Transaction
Day Range
4,495 4,567
Year Range
3,420 4,567
Want to track ABBV and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

ABBV closed today higher at MX$4,495, an increase of 3.7629% from yesterday's close, completing a monthly increase of 2.6256% or MX$115. Over the past 12 months, ABBV stock gained 8.7417%.
ABBV pays dividends to its shareholders, with the most recent payment made on May 15, 2026. The next announced payment will be in In 3 weeks on Aug 14, 2026 for a total of MX$1.73.
The last earnings report, released on Apr 23, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 13 different exchanges and in various currencies, with the primary listing on NYSE (USD).

ABBV Chart

Will AbbVie's Neuroscience Franchise Deliver Another Strong Quarter?

Will AbbVie's Neuroscience Franchise Deliver Another Strong Quarter?

ABBV's neuroscience business is expected to post solid Q2 growth, with key brands and Vyalev in focus ahead of earnings on July 31.

Zacks | 1 day ago
Should You Buy, Sell or Hold ABBV Stock After Its 9% YTD Rise?

Should You Buy, Sell or Hold ABBV Stock After Its 9% YTD Rise?

AbbVie ABBV stock has risen 8.9% so far this year as investor confidence strengthened in the company's post-Humira growth strategy. Despite Humira's U.S. patent expiry in 2023, AbbVie has successfully replaced much of the blockbuster's lost revenues with strong growth from Skyrizi and Rinvoq, easing concerns over its long-term earnings outlook.

Zacks | 2 days ago
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It

AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It

AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks | 2 days ago

AbbVie Inc. (ABBV) FAQ

What is the stock price today?

The current price is MX$4,495.00.

On which exchange is it traded?

AbbVie Inc. is listed on XMEX.

What is its stock symbol?

The ticker symbol is ABBV.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 1.58%.

What is its market cap?

As of today, no market cap data is available.

Has AbbVie Inc. ever had a stock split?

No, there has never been a stock split.

AbbVie Inc. Profile

Pharmaceuticals Industry
Healthcare Sector
Mr. Robert A. Michael CPA CEO
XMEX Exchange
US00287Y1091 ISIN
BR Country
57,000 Employees
15 Jul 2026 Last Dividend
- Last Split
2 Jan 2013 IPO Date

Overview

AbbVie Inc. is a global pharmaceutical company engaged in the discovery, development, manufacturing, and sales of a wide range of pharmaceutical products. Incorporated in 2012 and headquartered in North Chicago, Illinois, AbbVie focuses on addressing some of the world's most complex and critical health issues through its innovative medicines and therapies. In addition to its stand-alone operations, the company collaborates with several other leading institutions, including Calico Life Sciences LLC, REGENXBIO Inc., Janssen Biotech, Inc., Genentech, Inc., and Tentarix Biotherapeutics, LP. These collaborations aim to enhance AbbVie's research and development capabilities, particularly in the areas of oncology and immunology.

Products and Services

  • Humira: A therapeutic injection for various autoimmune diseases, including intestinal Behçet's disease and pyoderma gangrenosum.
  • Skyrizi: Prescribed for patients with moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease, focusing on improving skin health.
  • Rinvoq: Targets multiple conditions such as rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, and several gastrointestinal diseases.
  • Imbruvica: An oral medication for adults with various blood cancers, marking significant advancements in oncology.
  • Epkinly and Elahere: Treatments tailored for different forms of lymphoma and cancer, showcasing AbbVie's innovations in targeted therapies.
  • Venclexta/Venclyxto: Offers hope for patients battling blood cancers, through a regimen that interferes with cancer cell survival.
  • Aesthetic Products: A range of facial injectables, plastics and regenerative medicine, body contouring, and skincare offerings that cater to aesthetic needs.
  • Botox Therapeutic: Beyond cosmetic applications, this product is utilized for various therapeutic purposes, enhancing patient care.
  • Vraylar: A medication designed to address depressive disorder, contributing to mental health treatment options.
  • Duopa and Duodopa: These formulations provide relief for patients with advanced Parkinson's disease, improving quality of life.
  • Ubrelvy and Qulipta: Target the acute treatment of migraine in adults, including both episodic and chronic forms.
  • Ozurdex: An ocular implant designed to treat eye diseases, emphasizing AbbVie's contribution to ophthalmology.
  • Lumigan/Ganfort and Alphagan/Combigan: Aimed at reducing intraocular pressure in conditions like open-angle glaucoma or ocular hypertension.
  • Restasis: Helps increase tear production, addressing the needs of patients with dry eye disease.
  • Mavyret/Maviret: Administered for the treatment of chronic hepatitis C virus (HCV) infection, representing a breakthrough in HCV treatment.
  • Creon: A pancreatic enzyme therapy essential for patients with pancreatic insufficiency, aiding digestion.
  • Lupron: Utilized for treating advanced prostate cancer, endometriosis, central precocious puberty, and uterine fibroids-related anemia.
  • Linzess/Constella: Offers relief for irritable bowel syndrome with constipation and chronic idiopathic constipation.
  • Synthroid: A synthetic thyroid hormone used to treat hypothyroidism, ensuring thyroid hormone levels are balanced.

Contact Information

Address: 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400
Phone: 847 932 7900